Blend Therapeutics, an oncology treatment startup based in Watertown, has appointed a new head.
The cancer-treatment company said Monday that Drew Fromkin has been named its new president and chief executive. Fromkin previously led Newton-based Clinical Data, Inc., which was acquired by Forest Laboratories in 2011 for $1.2 billion. Since then, he has worked as a consultant, according to his LinkedIn page, and as an entrepreneur-in-residence at OrbiMed Advisors, according to the venture capital database Crunchbase.
Blend, co-founded by physicians from Harvard and MIT in 2011, recently raised $21 million from investors to further research into two cancer-fighting compounds. It has also said it would work with other pharmaceutical companies interested in using its drug delivery platform.
Advertisement
Jack Newsham can be reached at jack.newsham@globe.com. Follow him on Twitter @TheNewsHam.